Romeijn P, Lenthall R, Stavrou D, Melcher D, Ladyman H, Ritter M A
Department of Immunology, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Br J Cancer. 1994 Nov;70(5):799-803. doi: 10.1038/bjc.1994.402.
Monoclonal antibody MUC 2-63 recognises neurogenic tumours and has been used successfully for radioimaging human malignant gliomas. We now show that the MUC 2-63 antigen has the same tissue distribution and molecular weight range as the CD44 antigen and confirm the identity of these two molecules in blocking studies using MUC 2-63 and the CD44 anti-framework antibody F10-44-2. Thus not only MUC 2-63 but also other anti-CD44 monoclonal antibodies should prove useful in imaging and, perhaps, therapy of brain tumours.
单克隆抗体MUC 2-63可识别神经源性肿瘤，并已成功用于人类恶性胶质瘤的放射性成像。我们现在表明，MUC 2-63抗原与CD44抗原具有相同的组织分布和分子量范围，并在使用MUC 2-63和CD44抗构架抗体F10-44-2的阻断研究中证实了这两种分子的同一性。因此，不仅MUC 2-63，而且其他抗CD44单克隆抗体在脑肿瘤的成像以及可能的治疗中都应被证明是有用的。
